Search

Your search keyword '"Lainez, Nuria"' showing total 7 results
Start Over Author "Lainez, Nuria" Database Supplemental Index
7 results on '"Lainez, Nuria"'

3. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

Author

Pinto, Álvaro, Reig, Oscar, Iglesias, Clara, Gallardo, Enrique, García-del Muro, Xavier, Alonso, Teresa, Anguera, Georgia, Suárez, Cristina, Muñoz-Langa, José, Villalobos-León, Laura, Rodríguez-Sánchez, Ángel, Lainez, Nuria, Martínez-Ortega, Esther, Campayo, Marc, Velastegui, Alejandro, Rodriguez-Vida, Alejo, Villa-Guzmán, José C., Méndez-Vidal, Maria J., Rubio, Gustavo, García, Iciar, Capdevila, Laia, Lambea, Julio, Vázquez, Sergio, Fernández, Ovidio, Hernando-Polo, Susana, Cerezo, Sara, Santander, Carmen, García-Marrero, Rosa, Zambrana, Francisco, González-del Alba, Aranzazu, Lazaro-Quintela, Martin, Castellano, Daniel, Chirivella, Isabel, Anido, Urbano, Viana, Antonio, García, Arancha, Sotelo, Miguel, Arévalo, María Garrido, García-Donas, Jesús, Hernández, Carolina, Bolós, M. Victoria, Llinares, Julia, and Climent, Miguel A.

Abstract

Axitinib monotherapy obtained approval in pre-treated mRCC patients and recently in combination with pembrolizumab or avelumab in the first-line setting. However, patient profiles that may obtain increased benefit from this drug and its combinations still need to be identified.

Published
2022
Full Text
View/download PDF

4. Image-guided brachytherapy in cervical cancer: Experience in the Complejo Hospitalario de Navarra.

Author

Villafranca, Elena, Navarrete, Paola, Sola, Amaya, Muruzabal, Juan Carlos, Aguirre, Sara, Ostiz, Santiago, Sanchez, Carmen, Guarch, Rosa, Lainez, Nuria, and Barrado, Marta

Abstract

Abstract Purpose To evaluate dosimetric and clinical findings of MRI-guided HDR brachytherapy (HDR-B) for cervical carcinoma. Material and methods All patients had a CT, MRI and pelvic-paraaortic lymphadenectomy. Treatment: pelvic (+/−)para-aortic3D/IMRT radiotherapy (45 Gy), weekly cisplatin and HDR-B and pelvic node/parametrial boost 60 Gy until interstitial brachytherapy was done. Two implants: 2008–2011: 5 fractions of 6 Gy, 2011: 2016, 4 fractions of 7 Gy. MRI/TAC were done in each implant. The following were defined: GTV, CTH-HR, CTV-IR; OAR: rectum, bladder and sigmoid. Results From 2007 to 2016: 57 patients. Patients: T1b2-T2a: 4p, T2b 41p, T3a: 2p; T3B 8p T4a: 2p; N0: 32p, N1 21p, no lymphadenectomy: 4p. Median follow up: 74.6 m (16–122 m), recurrence: 5p local, 6p node, 9p metastasis and 37p without recurrence. Local control 5 years: 90.1%; Ib2-IIB: 94.8%, III-IVa: 72.2%. (p :0.01). RDFS 5y was 92.5%; IB2-IIB: 93%, III: 85% (p :0.024); for pN0: 100%; pN+ iliac-paraaortic: 71.4% (p : 0.007). MFS 5y was 84.1%. Overall survival (OS) at 5y: 66.6% and the cancer specific survival (CEOS) was 74%. Univariate analysis survival: stage Ib2-II 83% vs. III-IVa 41% (p = 0.001); histology: squamous 78%, adenocarcinoma 59.7% (p : ns); lymph node: N0 85% vs. PA+P− 72%, and PA+P+ 35% (p = 0.010). In relation with: HR-CTV dose > 85 Gy, CEOS: 82.5% vs. 77%, and volume CTV-HR < 30 cc: 81.8% and >30 cc: 67%; p : ns. Acute grade 2–3 toxicity: rectal 15.7%, intestinal 15.7% and vesical 15.5%. Conclusion Use of interstitial HDR-BQ guided by RM increased CTV-HR dose and local control, like EMBRACE results. Nodal boost improves RDFS and perhaps OS. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

5. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents

Author

Angelergues, Antoine, Efstathiou, Eleni, Gyftaki, Revekka, Wysocki, Piotr Jan, Lainez, Nuria, Gonzalez, Iria, Castellano, Daniel E., Ozguroglu, Mustafa, Carbonero, Iciar Garcia, Flechon, Aude, Borrega, Pablo, Guillot, Aline, Balea, Begona Campos, Le Moulec, Sylvestre, Esteban, Emilio, Munarriz, Javier, Rubio, Gustavo, Birtle, Alison J., Delanoy, Nicolas, Bellmunt, Joaquim, and Oudard, Stéphane

Abstract

Several agents have demonstrated an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC); however, optimal sequencing is unknown. Retrospective analysis of data from 574 mCRPC patients showed increasing OS with the number of therapies provided; a sequence including docetaxel, cabazitaxel (CABA), and an androgen receptor–targeted agent (ART) provided the greatest benefit. Prior administration of ART did not appear to influence CABA activity. These findings will help guide treatment decisions in daily practice.

Published
2018
Full Text
View/download PDF

6. SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma

Author

Duran, Ignacio, Hagen, Carlos, Arranz, José Ángel, Apellaniz-Ruiz, María, Pérez-Valderrama, Begoña, Sala, Nuria, Lainez, Nuria, García-Del Muro, Xavier, Noguerón, Esther, Climent, Miguel Ángel, Maroto, Pablo, Font, Albert, García-Donas, Jesús, Gallardo, Enrique, López-Criado, Pilar, González Del Alba, Aránzazu, Sáez, María Isabel, Vázquez, Sergio, Luque, Raquel, and Rodríguez-Antona, Cristina

Abstract

Aim:We aimed to identify SNPs associated with cabazitaxel toxicity and response within a Phase II clinical trial using this compound in advanced transitional cell carcinoma after progression to a platinum-based regimen. Patients & methods:Eleven SNPs in CYP3A4, CYP3A5, CYP2C8, ABCB1and TUBB1were genotyped in 45 patients. Results:CYP3A5rs776746 A allele was associated with protection against gastrointestinal toxicity (odds ratio: 0.06, 95 CI: 0.007–0.63, p 0.018) and with reduced progression-free survival (hazard ratio: 5.1, 95 CI: 1.7–15.1, p 0.0038, multivariable analysis). ABCB1SNPs were associated with total number of grade 3–4 toxicity events (p-values of 0.009, 0.041 and 0.043, respectively). Conclusion:Polymorphisms in CYP3A5and ABCB1may define a subset of patients with different cabazitaxel toxicity and efficacy and therefore could be used as markers for treatment optimization.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results